Skip to content
lifestyle.friendhood.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Arvinas Inc.
Arvinas to Participate in Upcoming Investor Conferences
September 3, 2026
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 1, 2026
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
July 28, 2026
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 5, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 3, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 3, 2026
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
March 11, 2026
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
February 13, 2026